Blog

Aaaaaand we’re back! VBCF staff and volunteers spent September and October traveling and presenting to groups across the Commonwealth, totaling 30 educational events…27 in October. We got to speak to thousands of Virginians about breast health, from Wythe County to Portsmouth, from Fairfax to Suffolk. We donned hard hats and judged pumpkin painting contests. We…
Read more

During the month of October, we had our inaugural Sole Stars campaign in Lynchburg. We had 14 community leaders don pink shoes and raise funds to support VBCF. The campaign started with a modest goal of $16,000. These Sole Stars are actually ROCK STARS and raised an astounding $63,847.31! A big thank you to each…
Read more

Saturday, October 22, was an absolutely beautiful day in Abingdon, Virginia!  We had 40+ in-person participants join us on the Virginia Creeper Trail to walk, bike, and run 13.1 Miles as part of the 2nd Annual Pink 13.1!  We had another 15 participants join us virtually from Christiansburg, Roanoke, Harrisonburg, and Richmond. The Second Annual…
Read more

The Power of Pink Luncheon took place on Monday, October 3 in Roanoke.  The Second Annual Luncheon was a huge success -raising funds and awareness for the Virginia Breast Cancer Foundation.  It was sponsored by Blue Ridge Cancer Care, Kroger, Berglund Cars, Branch Group, Fink’s Jewelers and Boxley.  We are so appreciative of all our sponsors. …
Read more

We talk a lot about advocating for yourself as a patient here at VBCF, but what does that actually look like? Tara Daudani, the Vice President of our VBCF Board, talks about advocating for herself while going through her breast cancer treatment, what she looks for in a healthcare provider, and how she prepares to…
Read more

On Friday, September 30th, VBCF kicked off Breast Cancer Awareness Month with a celebration of accomplishments in breast cancer education and advocacy in Virginia at our 3rd Annual More than a Pink Ribbon Awards luncheon held at Lewis Ginter Botanical Garden in Richmond. 

At the American Society for Clinical Oncology (ASCO) conference earlier this year, a new breast cancer drug received a standing ovation after researchers announced the results of their trial. This drug is Enhertu, and it was recently approved by the FDA to treat people with a certain type of metastatic breast cancer. VBCF doesn’t tend to report on specific drugs for breast cancer treatment because treatment is so individualized – one treatment that works wonders for one person could be ineffective for another. The reason Enhertu warrants some discussion is that it essentially creates a new type of breast cancer that can be a new research focus: HER2-low.